NASDAQ:MGTA

Magenta Therapeutics Competitors

$12.32
-1.22 (-9.01 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.14
Now: $12.32
$13.57
50-Day Range
$9.24
MA: $12.25
$14.15
52-Week Range
$6.03
Now: $12.32
$14.20
Volume144,965 shs
Average Volume311,083 shs
Market Capitalization$598.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46

Competitors

Magenta Therapeutics (NASDAQ:MGTA) Vs. CYRX, XNCR, AMRN, RCUS, PBH, and IGMS

Should you be buying MGTA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Magenta Therapeutics, including Cryoport (CYRX), Xencor (XNCR), Amarin (AMRN), Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), and IGM Biosciences (IGMS).

Cryoport (NASDAQ:CYRX) and Magenta Therapeutics (NASDAQ:MGTA) are both transportation companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Cryoport and Magenta Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
Magenta Therapeutics00403.00

Cryoport presently has a consensus price target of $72.00, indicating a potential upside of 37.69%. Magenta Therapeutics has a consensus price target of $17.6667, indicating a potential upside of 43.40%. Given Magenta Therapeutics' higher possible upside, analysts clearly believe Magenta Therapeutics is more favorable than Cryoport.

Volatility and Risk

Cryoport has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.

Insider and Institutional Ownership

88.3% of Cryoport shares are owned by institutional investors. Comparatively, 59.3% of Magenta Therapeutics shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 10.9% of Magenta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cryoport and Magenta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95

Cryoport has higher revenue and earnings than Magenta Therapeutics. Cryoport is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cryoport and Magenta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
Magenta TherapeuticsN/A-53.42%-47.67%

Summary

Cryoport beats Magenta Therapeutics on 8 of the 12 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Magenta Therapeutics and Xencor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
Xencor20702.56

Magenta Therapeutics presently has a consensus target price of $17.6667, indicating a potential upside of 43.40%. Xencor has a consensus target price of $47.1111, indicating a potential upside of 16.41%. Given Magenta Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Magenta Therapeutics is more favorable than Xencor.

Volatility & Risk

Magenta Therapeutics has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Institutional and Insider Ownership

59.3% of Magenta Therapeutics shares are held by institutional investors. 10.9% of Magenta Therapeutics shares are held by insiders. Comparatively, 3.7% of Xencor shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Magenta Therapeutics and Xencor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95
Xencor$156.70 million14.97$26.88 million$0.4687.98

Xencor has higher revenue and earnings than Magenta Therapeutics. Magenta Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Magenta Therapeutics and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
Xencor-113.40%-13.56%-12.03%

Summary

Magenta Therapeutics beats Xencor on 7 of the 13 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Amarin (NASDAQ:AMRN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Magenta Therapeutics and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
Amarin03802.73

Magenta Therapeutics presently has a consensus target price of $17.6667, indicating a potential upside of 43.40%. Amarin has a consensus target price of $11.1818, indicating a potential upside of 88.56%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than Magenta Therapeutics.

Volatility & Risk

Magenta Therapeutics has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500.

Institutional and Insider Ownership

59.3% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 37.8% of Amarin shares are held by institutional investors. 10.9% of Magenta Therapeutics shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Magenta Therapeutics and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95
Amarin$429.76 million5.43$-22,650,000.00($0.07)-84.71

Amarin has higher revenue and earnings than Magenta Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Magenta Therapeutics and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
Amarin-2.69%-2.70%-1.72%

Summary

Amarin beats Magenta Therapeutics on 8 of the 13 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

59.3% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are held by institutional investors. 10.9% of Magenta Therapeutics shares are held by insiders. Comparatively, 19.7% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Magenta Therapeutics and Arcus Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
Arcus Biosciences-112.63%-27.43%-20.96%

Risk and Volatility

Magenta Therapeutics has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Magenta Therapeutics and Arcus Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
Arcus Biosciences00903.00

Magenta Therapeutics currently has a consensus target price of $17.6667, indicating a potential upside of 43.40%. Arcus Biosciences has a consensus target price of $49.9091, indicating a potential upside of 59.45%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Magenta Therapeutics.

Valuation and Earnings

This table compares Magenta Therapeutics and Arcus Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95
Arcus Biosciences$15 million147.89$-84,710,000.00($1.93)-16.22

Magenta Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arcus Biosciences beats Magenta Therapeutics on 8 of the 12 factors compared between the two stocks.

Prestige Consumer Healthcare (NYSE:PBH) and Magenta Therapeutics (NASDAQ:MGTA) are both consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Institutional & Insider Ownership

59.3% of Magenta Therapeutics shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 10.9% of Magenta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Prestige Consumer Healthcare and Magenta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million2.27$142.28 million$2.9614.78
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95

Prestige Consumer Healthcare has higher revenue and earnings than Magenta Therapeutics. Magenta Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Prestige Consumer Healthcare and Magenta Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare04302.43
Magenta Therapeutics00403.00

Prestige Consumer Healthcare currently has a consensus price target of $87.60, indicating a potential upside of 100.23%. Magenta Therapeutics has a consensus price target of $17.6667, indicating a potential upside of 43.40%. Given Prestige Consumer Healthcare's higher probable upside, equities analysts clearly believe Prestige Consumer Healthcare is more favorable than Magenta Therapeutics.

Volatility & Risk

Prestige Consumer Healthcare has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.

Profitability

This table compares Prestige Consumer Healthcare and Magenta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare17.03%13.76%4.80%
Magenta TherapeuticsN/A-53.42%-47.67%

Summary

Prestige Consumer Healthcare beats Magenta Therapeutics on 8 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and Magenta Therapeutics (NASDAQ:MGTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares IGM Biosciences and Magenta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
Magenta TherapeuticsN/A-53.42%-47.67%

Valuation & Earnings

This table compares IGM Biosciences and Magenta Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95

IGM Biosciences is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

IGM Biosciences has a beta of -1.12, meaning that its stock price is 212% less volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 59.3% of Magenta Therapeutics shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by company insiders. Comparatively, 10.9% of Magenta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for IGM Biosciences and Magenta Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
Magenta Therapeutics00403.00

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. Magenta Therapeutics has a consensus price target of $17.6667, indicating a potential upside of 43.40%. Given IGM Biosciences' higher probable upside, equities analysts clearly believe IGM Biosciences is more favorable than Magenta Therapeutics.

Summary

IGM Biosciences beats Magenta Therapeutics on 6 of the 11 factors compared between the two stocks.


Magenta Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
High Trading Volume
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.